3 completed, 3 unknown, 1 not yet recruiting, 1 recruiting. 8 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 3, Unknown 3, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
Follow mFOLFOX6 regimen: new trials by email Literature Review of mFOLFOX6 regimen trials Research Report on mFOLFOX6 regimen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NCT + PD1 + Ketogenic Diet and/or Vitamin C for LARC Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen - Rectal Adenocarcinoma, High-Risk Cancer | Phase 2 | Not yet recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 100 | 2026-09-01 | 2026-08-14 |
| SCRT+mFOLFOX6+PD-1 Antibody and Targeted Therapy for High-Risk pMMR/MSS Rectal Cancer Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen - Rectal Adenocarcinoma, High-Risk Cancer | Phase 2 | Completed | Sixth Affiliated Hospital, Sun Yat-sen University | 49 | 2025-04-02 | 2026-08-04 |
| Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors RMC-6236, mFOLFOX6 regimen, bevacizumab - Colorectal Cancer, CRC | Phase 1 / Phase 2 | Recruiting | Revolution Medicines, Inc. | 1130 | 2024-05-24 | 2026-09-22 |
| Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer Camrelizumab, Trastuzumab, XELOX regimen - Colorectal Neoplasms, Intestinal Neoplasms | Phase 2 | Unknown | Fudan University | 77 | 2022-01-01 | 2022-01-14 |
| Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer Bevacizumab, mFOLFOX6 regimen, mOXXEL regimen - Ras-mutated Metastatic Colorectal Cancer | Phase 2 | Unknown | National Cancer Institute, Naples | 200 | 2019-05-24 | 2023-11-13 |
| Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6 Paclitaxel, mFOLFOX6 regimen - Gastric Cancer Stage IV, Peritoneal Carcinomatosis | Phase 1 / Phase 2 | Completed | Seoul National University Bundang Hospital | 35 | 2018-12-24 | 2023-12-05 |
| FOLFOX6 as Neoadjuvant Chemotherapy in Local Advanced Gastric Cancer mFOLFOX6 regimen - Gastric Cancer, Effects of Chemotherapy | Phase 2 | Unknown | Peking Union Medical College Hospital | 75 | 2013-10-01 | 2014-08-27 |
| Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer ABT-869, bevacizumab, oxaliplatin - Advanced Colorectal Cancer, Adenocarcinoma of the Colon | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 159 | 2008-10-01 | 2013-05-15 |
Colorectal Neoplasms (3) · Rectal Neoplasms (3) · Stomach Neoplasms (2) · Carcinoma, Pancreatic Ductal (1) · Colonic Neoplasms (1) · Gastrointestinal Neoplasms (1) · Intestinal Neoplasms (1) · Pancreatic Neoplasms (1) · Peritoneal Neoplasms (1)
Sixth Affiliated Hospital, Sun Yat-sen University (2) · AbbVie (prior sponsor, Abbott) (1) · Fudan University (1) · National Cancer Institute, Naples (1) · Peking Union Medical College Hospital (1) · Revolution Medicines, Inc. (1) · Seoul National University Bundang Hospital (1)
China (4) · South Korea (2) · United States (2) · Australia (1) · Belgium (1) · Brazil (1) · Canada (1) · Czechia (1) · Greece (1) · Italy (1) · New Zealand (1) · Poland (1) · Portugal (1) · Romania (1) · Russia (1)
Alfredo Budillon, MD (1) · Antonio Avallone, MD (1) · Guohui Wan, PhD. (1) · Hyung-Ho Kim, M.D., PhD. (1) · Juan Huang, PhD. (1) · Jun Huang, PhD. (1) · Maria Carmela Piccirillo, MD (1) · Mark D. McKee, MD (1) · Xiang Wang, Master (1)
PMID 22189752, PMID 32849914, PMID 40056080
2018 (1)